Accessibility Menu
Bioventix Plc logo

Bioventix Plc(LSE) BVXP

Market Cap£78.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+1,499%
5 Year-62%
1 Year-44%
1 Month-8%
£15.10
+0.52%
+0.08Today
Bioventix Plc last closing stock price
MetricPriceDate
Last closeGBX 1,510.002026-07-30
Bioventix Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.67%GBX 1,500.002026-07-23
1 month-8.48%GBX 1,650.002026-06-30
3 month-12.46%GBX 1,725.002026-05-01
Year to date-20.73%GBX 1,905.002025-12-31
1 year-43.55%GBX 2,675.002025-07-30
3 year-60.26%GBX 3,800.002023-07-31
5 year-61.77%GBX 3,950.002021-07-30
Since inception+1,499.01%GBX 0.942010-04-07

Bioventix Plc Financials at a Glance

Market Cap

£78.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£26.21M

Net Income (TTM)

£15.28M

EPS (TTM)

£1.41

P/E Ratio

10.61

Dividend

£1.50

Beta (Volatility)

-0.00 (Low)

Price

£15.10

Volume

15,550

Open

£15.10

Previous Close

£15.10

Daily Range

£15.10 - £15.10

52-Week Range

£13.20 - £27.00

Estimated Earnings Date

Oct 26, 2026

BVXP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bioventix Plc

Bioventix PLC specializes in the development and manufacturing of sheep monoclonal antibodies (SMAs) for diagnostic applications. The company offers a diverse range of products that support testing in critical health areas, including thyroid conditions, cardiac health, and infectious diseases.

Products and Services
  • Purified sheep monoclonal antibodies for various diagnostic tests
  • Tailored contract SMA development services
  • Specialized recombinant services for medical applications
Growth Outlook
  • Strong demand for diagnostic tests is driving revenue growth
  • Expansion into new markets enhances product reach and sales potential
  • Continued investment in R&D supports innovation and product development
Financial Highlights
  • Recent quarterly revenue of £6.16 million, reflecting robust performance
  • Trailing twelve months (TTM) net profit margin of 59.3% indicates strong profitability
  • Dividend yield of 9.38% showcases commitment to returning value to shareholders
Bioventix PLC has established itself as a key player in the biotechnology sector, focusing on innovative diagnostic solutions. The company's product offerings are essential for various medical conditions, positioning it well for future growth. The strong financial performance, highlighted by a significant net profit margin and a healthy dividend yield, reflects the company's operational efficiency and commitment to shareholder value. With ongoing investments in research and development, Bioventix is poised to capitalize on the growing demand for diagnostic testing, making it an intriguing option for potential investors.
AI Generated • Jul 13, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Peter J. Harrison

Website

www.bioventix.com

Headquarters

Farnham, SU GU9 7SX, GB

BVXP Financials

Key Financial Metrics (TTM)

Gross Margin

91.93%

Operating Margin

75.62%

Net Income Margin

59.30%

Return on Equity

65.83%

Return on Capital

85.73%

Return on Assets

57.06%

Earnings Yield

9.43%

Dividend Yield

9.93%

Payout Ratio

1.05%

Stock Overview

Market Cap

£78.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.22M

Volume

15.55K

Avg. Volume

9.01K

Financials (TTM)

Gross Profit

£23.85M

Operating Income

£19.79M

EBITDA

£19.88M

Operating Cash Flow

£15.71M

Capital Expenditure

-£62.53K

Free Cash Flow

£15.65M

Cash & ST Invst.

£5.30M

Total Debt

£0.00

Bioventix Plc Performance Analysis

Bioventix Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 11,719,271N/A
20232023-06-30GBP 12,816,2259.4%
20242024-06-30GBP 13,606,5846.2%
20252025-06-30GBP 13,115,869-3.6%
Bioventix Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-303.8%
Q22024-12-31-2.9%
Q42025-06-30-5.2%
Q22025-12-31-3.5%
Bioventix Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP 1.46N/A
20232023-06-30GBP 1.588.5%
20242024-06-30GBP 1.53-3.4%
20252025-06-30GBP 1.43-6.3%
Bioventix Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-302.6%
Q22024-12-31-9.0%
Q42025-06-301.4%
Q22025-12-31-5.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£6.16M

-7.7%

Gross Profit

£5.62M

-9.7%

Gross Margin

91.24%

N/A

Market Cap

£78.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£4.64M

N/A

Employees

17

N/A

Net Income

£3.63M

-9.9%

EBITDA

£4.59M

-12.0%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£5.30M

-3.7%

Total Debt

£0.00

N/A

Accounts Receivable

£6.17M

+4.1%

Inventory

£723.30K

+23.5%

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

57.06%

N/A

Return on Invested Capital

85.90%

N/A

Free Cash Flow

£4.40M

+0.2%

Operating Cash Flow

£4.44M

+0.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SCLP.LScancell Holdings plc
£0.10-1.01%
HVO.LhVIVO plc
£0.08+6.90%
EKF.LEKF Diagnostics Holdings plc
£0.26-0.77%
HEMO.LHemogenyx Pharmaceuticals Plc
£6.33-1.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About BVXP

What is the current price of Bioventix Plc?

Bioventix Plc is trading at £15.10 per share.

What is the 52-week range for Bioventix Plc?

Over the past 52 weeks, Bioventix Plc has traded between £13.20 and £27.00.

How much debt does Bioventix Plc have?

As of the most recent reporting period, Bioventix Plc reported total debt of £0.00.

How much cash does Bioventix Plc have on hand?

Bioventix Plc reported £5.08M in cash and cash equivalents in its most recent financial results.

What is Bioventix Plc’s dividend yield?

Bioventix Plc currently has a dividend yield of 9.93%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services